In glioma, the miR-181 family is well-verified as inhibitory miRNAs targeting MGMT, BCL-2 and KPNA4 [1,2,3], while miR-21, an oncogenic miRNA, was found to accelerate glioma progression and could be suppressed by small molecular drugs with high efficiency [40]; whereas, the miRNAs with TACC3 mRNA 3′ untranslational region binding capability have not been investigated. This evidence concerns the gene BCL2 and central nervous system cancer.